Group | CD117+ | CD117- | p value | |
---|---|---|---|---|
MGUS | Tot CD34+ | 1.47 | 1.19 | NS |
(0.50–2.46) | (0.30–1.63) | |||
CD34 + CD19- | 95.49 | 86.72 | NS | |
(82.58–97.99) | (85.73–96.34) | |||
CD34 + CD19+ | 4.51 | 13.28 | NS | |
(2.01–17.42) | (3.66–14.27) | |||
Ratio | 21.17 | 6.53 | NS | |
(4.74–48.75) | (6.01–26.32) | |||
Therapy | Tot CD34+ | 0.73 | 1.83 | 0.013 |
(0.14–2) | (0.85–2.84) | |||
CD34 + CD19- | 78.71 | 70.97 | NS | |
(33.91–98.71) | (62.86–91.42) | |||
CD34 + CD19+ | 21.29 | 29.04 | NS | |
(1.29–66.09) | (8.58–37.14) | |||
Ratio | 4.27 | 2.50 | NS | |
(0.51–76.52) | (1.69–10.66) | |||
New | Tot CD34+ | 1.80 | 0.56 | 0.018 |
(0.49–2.61) | (0.06–1.22) | |||
CD34 + CD19- | 82.42 | 94.59 | 0.003 | |
(74.98–87.70) | (90–98.89) | |||
CD34 + CD19+ | 17.58 | 5.41 | 0.003 | |
(12.30–25.02) | (1.11–10) | |||
Ratio | 4.69 | 17.48 | 0.003 | |
(3–7.13) | (9–89.09) | |||
Progressive | Tot CD34+ | 0.80 | 0.60 | NS |
(0.22–0.87) | (0.23–0.62) | |||
CD34 + CD19- | 88.75 | 77.88 | 0.036 | |
(80.79–94.83) | (75.73–80.77) | |||
CD34 + CD19+ | 11.25 | 22.12 | 0.036 | |
(5.17–19.21) | (19.23–24.27) | |||
Ratio | 7.89 | 3.52 | 0.036 | |
(4.21–18.34) | (3.12–4.20) |